Feb 24, 2021
Soligenix Provides Important Highlights and Upcoming Catalysts in Corporate Update Letter
Jan 19, 2021
Soligenix Announces Investor Webcast Event: U.S. Commercialization of SGX301 in the Treatment of Cutaneous T-Cell Lymphoma
Jan 07, 2021
Soligenix Announces Strategic Partnership with Daavlin for Supply and Distribution of the SGX301 Companion Light Device in the Treatment of Cutaneous T-Cell Lymphoma
Dec 28, 2020
Soligenix Announces $1.5 Million NIH Small Business Innovation Research Award Advancing COVID-19 Vaccine Development
Dec 22, 2020
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Nov 12, 2020
Soligenix Announces Recent Accomplishments And Third Quarter 2020 Financial Results
Nov 10, 2020
Soligenix Invited to Present at Upcoming Virtual Investor Conferences
Oct 08, 2020
Soligenix to Present at the BIO Investor Forum
Sep 15, 2020
Soligenix Announces Publication Demonstrating Thermostabilization of Filovirus Vaccine Antigens
Sep 10, 2020
Soligenix Announces Investor Webcast Event and Presentation Today: Advantages of the CiVax(TM) Program for Development of a Broadly Distributed Heat Stable COVID-19 Vaccine
Sep 09, 2020
Soligenix Invited to Present at Upcoming Virtual Investor Conferences
Aug 27, 2020
Soligenix to Present at the LD Micro Conference
Aug 14, 2020
Soligenix Announces Recent Accomplishments And Second Quarter 2020 Financial Results
Jul 28, 2020
Soligenix Announces Publication of Positive Pre-clinical Results for a Novel COVID-19 Vaccine
Jul 20, 2020
Soligenix Issues Corporate Update - Highlights Important Catalysts for Second Half of 2020
Jun 24, 2020
Soligenix Completes Enrollment in its Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis
Jun 22, 2020
Soligenix to Join Russell Microcap® Index
Jun 09, 2020
Soligenix to Present at the MedInvest Infectious Disease and Immunology Investor Conference
May 15, 2020
Soligenix Announces Recent Accomplishments And First Quarter 2020 Financial Results
May 11, 2020
Soligenix Announces Publication of Correlates of Immune Protection for the RiVax® Ricin Toxin Vaccine